Trevi Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Trevi Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, and is seeking shareholder approval to increase its authorized common stock and amend its stock incentive plan.
NASDAQ
DEFA14A: Trevi Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals for Stockholder Vote
Trevi Therapeutics has scheduled its 2025 Annual Meeting for June 11, 2025, and is seeking stockholder votes on director elections, auditor ratification, executive compensation, and an amendment to the stock incentive plan.
NASDAQ
Trevi Therapeutics is holding its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to vote on key proposals including director elections and an amendment to the company's stock incentive plan.
NASDAQ
Trevi Therapeutics is holding its annual meeting of stockholders on June 13, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its auditor.
NASDAQ
Trevi Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.